The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; U.S. only), as well as BRAF/MEK inhibitor combinations such as Roche / Genentech’s Zelboraf plus Cotellic, Novartis’s Tafinlar plus Mekinist, and Pfizer / Array BioPharma’s Braftovi plus Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underrepresented BRAF wild-type unresectable or metastatic population. With the expected introduction of novel agents and combination regimens, the malignant melanoma treatment paradigm will continue to evolve.
Questions answered:
- How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? Will drug treatment rates increase over the forecast period?
- What is the current treatment landscape in malignant melanoma? Which currently approved drugs are the most prescribed and why?
- Which drugs in late-phase development are poised to change the treatment of malignant melanoma and how? What sales / uptake could these drugs secure in the malignant melanoma market?
- What are the key drivers of / constraints in the malignant melanoma therapy market, and how will the market evolve over the forecast period?
Content highlights
Geographies: United States, EU5, Japan.
Primary research: 16 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.
Epidemiology: Incidence of malignant melanoma by country, segmented by BRAF mutation status, disease stage, and line of therapy.
Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2031, segmented by brands / generics / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase III: 5 drugs; Phase II: 1 drug; coverage of select early-phase products.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast features continual updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Saurabh Virdi
Saurabh Virdi, B.Tech., is an analyst on the Oncology team at Clarivate. He has more than seven years working in the pharmaceutical industry providing analytical support in various therapy areas, including oncology, HIV, vaccines, specialty pharma, and rare diseases. Prior to joining Clarivate, he was an assistant project manager at DelveInsight Business Research LLP, where he was responsible for developing and delivering customized market and asset value forecasts. Before DelveInsight, he worked at WNS GSK Knowledge center and SmartAnalyst, where, as part of multifunctional teams, he helped clients’ decision making throughout the development journey from early-stage to marketed drugs. He obtained his bachelor’s degree in biotechnology from Delhi Technological University in India.
Surup Dey
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.